AAVXF (Abivax) Notes Receivable: $0.00 Mil (As of Mar. 2026)


AAVXF Abivax SA AAVXF
25 GF Score
Price $80.03
! 1 Warning Sign
View Full Analysis

What is Abivax Notes Receivable?

Abivax AAVXF -20.96% 25 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates AAVXF with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Abivax's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Abivax's quarterly Notes Receivable declined from Sep. 2025 ($0.01 Mil) to Dec. 2025 ($0.00 Mil) but then stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Abivax's annual Notes Receivable declined from Dec. 2023 ($0.07 Mil) to Dec. 2024 ($0.05 Mil) and declined from Dec. 2024 ($0.05 Mil) to Dec. 2025 ($0.00 Mil).

Abivax Notes Receivable Historical Data

* Premium members only.

The historical data trend for Abivax's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax Notes Receivable Chart

Abivax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.27 0.07 0.05 0.00

Abivax Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.08 0.01 0.00 0.00
AAVXF
25GF Score
Abivax SA AAVXF
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Abivax (AAVXF) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Abivax and its competitors.
Is Abivax's Notes Receivable too high?
Abivax's current Notes Receivable is $0.00 Mil. Overall, Abivax has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Abivax's Notes Receivable compare to VRTX and REGN?
Abivax's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Abivax and its competitors. Abivax's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abivax stock overvalued right now?
Abivax (AAVXF) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Abivax's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Abivax (AAVXF), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
25GF Score

Get the complete analysis for AAVXF

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$80.03
Price